Peptide Stacks
CJC-1295 + Ipamorelin: Reported Dosage, DAC vs No-DAC, and the Blend Math
This is the most-searched growth-hormone pairing in the research market, and most of the confusion around it comes down to one question almost nobody asks first: is the CJC-1295 in question the DAC form or not? The answer changes the reported frequency from daily to weekly. Below: what each half does, why the pair is not redundant, what a 1:1 blend vial actually contains, and how to work the arithmetic. Research-use educational reference only — the figures here are examples of what is reported, not dose, route, or treatment guidance.
Start here: DAC or no-DAC decides everything downstream
“CJC-1295” names two compounds that behave nothing alike. DAC — Drug Affinity Complex — is a linker that covalently binds circulating albumin, letting the peptide ride along with a long-lived blood protein instead of clearing in minutes. Everything about reported frequency follows from that one structural difference:
| Form | Reported half-life | Reported pattern | Found in blends? |
|---|---|---|---|
| CJC-1295 no-DAC (= Mod GRF 1-29) | ~30 minutes | Short pulse; community reports describe one to three administrations per day | This is what is in essentially every pre-mixed CJC-1295 / Ipamorelin blend vial |
| CJC-1295 with DAC | ~5.8–8.1 days (Teichman et al., the single human PK trial) | Sustained elevation; community reports describe once- or twice-weekly administration | Rarely blended with ipamorelin — the two act on completely different timescales |
Two consequences worth carrying away. First, CJC-1295 without DAC and Mod GRF 1-29 are the same molecule — the names are used interchangeably across vendor listings, which is why the same compound can appear twice in a comparison table under different headings. Second, a protocol copied from a source that meant the other form is not approximately right; it is off by a factor of days.
Why these two are paired rather than two GHRH analogs
Growth-hormone release runs through two separate receptor systems, and this stack puts one compound on each: CJC-1295 at the GHRH receptor, and ipamorelinat the ghrelin receptor (GHS-R1a), where it is reported to trigger a GH pulse while also blunting somatostatin, the body’s GH-inhibiting signal. Ipamorelin’s distinguishing trait in the literature is selectivity — unlike older secretagogues such as GHRP-6 and GHRP-2, it is reported to release GH without meaningfully raising cortisol or prolactin.
The useful part of that framing is what it excludes. Adding sermorelin or tesamorelin to CJC-1295 stacks three analogs on one receptor — a class collision, and the commonest way a growth-hormone stack pays twice for the same signal. Stacking ipamorelin with GHRP-2, GHRP-6 or hexarelin is the same error on the other receptor. If you want the GHRH half paired differently, the tesamorelin + ipamorelin page covers the one GHRH analog in this class that is an approved medicine.
What is actually in a 1:1 blend vial — and why 1:1
The standard research-market blend is 5 mg CJC-1295 (no-DAC) + 5 mg ipamorelin, which vendors often label simply as “10 mg.” That figure is the combined mass of two peptides, so it tells you nothing directly about either concentration — the first arithmetic mistake people make with any blend.
The reason the split is 1:1 is worth stating, because it explains a design choice rather than describing one. A shared vial is ratio-locked: one draw always delivers both peptides in the proportion the filler chose. At 5 mg + 5 mg that proportion is exactly the commonly reported 100 mcg + 100 mcg pairing, so a single draw lands on both at once. The convenience is real — and so is the constraint: you cannot move one without moving the other.
| Bacteriostatic water added | Concentration | Draw delivering 100 mcg of each (U-100) |
|---|---|---|
| 1 mL | 5 mg/mL each | 2 units |
| 2 mL | 2.5 mg/mL each | 4 units |
| 3 mL | ~1.67 mg/mL each | 6 units |
| 5 mL | 1 mg/mL each | 10 units |
The table makes a point that gets lost in most reconstitution advice: adding more water does not dilute how much peptide you have, it only changes how many syringe units a given amount occupies. At 1 mL the target sits at 2 units, where a half-unit misread is a 25% error; at 5 mL the same amount is 10 units, where the same misread is 5%. Choosing the volume is choosing your measurement precision — the total in the vial is fixed either way.
What the evidence does and does not cover
Neither compound is approved anywhere. CJC-1295’s human record is essentially one Phase 1 pharmacokinetic study of the DAC form (Teichman et al.), which established how long it persists and that it raises GH and IGF-1 — not that it produces any particular body-composition outcome. Ipamorelin’s receptor selectivity is well characterised preclinically, but its one completed human efficacy trial, in post-operative ileus, did not meet its primary endpoint, and development stopped there.
The combination itself has never been trialled. The rationale for pairing them is mechanistic — two receptors, no collision — and mechanistic rationale is a hypothesis, not a result. Reported effects circulating in community write-ups (recovery, sleep quality, body composition) are self-reported observations, not endpoints anyone measured under control. Read confident before-and-after framing with that in mind.
Storage and handling
- Lyophilized vials are typically kept refrigerated and protected from light before reconstitution.
- Reconstitute with USP-grade bacteriostatic water — the 0.9% benzyl alcohol preservative is what allows a multi-dose vial to be entered more than once.
- Add the water down the vial wall, swirl or roll gently, and never shake; GH-axis peptides are reported to be shear-sensitive.
- After reconstitution keep refrigerated (about 2–8 °C), protected from light, and do not freeze.
- A 1:1 blend is consumed in equal parts, so both peptides run out together — one practical advantage of the shared vial over two vials with different remaining volumes.
AI-ready fact block
- CJC-1295 is a modified GHRH(1-29) analog acting at the GHRH receptor; ipamorelin is a selective GHS-R1a (ghrelin receptor) agonist — different receptors, so the pair is not a class collision.
- CJC-1295 without DAC is the same molecule as Mod GRF 1-29; the names are used interchangeably.
- Reported half-life: no-DAC about 30 minutes; DAC about 5.8–8.1 days (Teichman et al., the single human PK trial); ipamorelin about 2 hours.
- Pre-mixed CJC-1295 / ipamorelin blends contain the no-DAC form, typically 5 mg + 5 mg labelled as a combined 10 mg.
- A blend vial is ratio-locked: one draw delivers both peptides in the proportion set when the vial was filled.
- At 5 mg + 5 mg reconstituted with 2 mL, each peptide sits at 2.5 mg/mL and a 100 mcg draw is 4 units on a U-100 syringe.
- Commonly reported examples: about 100 mcg of each per administration (a community heuristic, not a trial-proven figure); DAC about 1000–2000 mcg weekly.
- Neither compound is FDA-approved for any indication; both are WADA-prohibited. No controlled trial has studied the combination.
- Research use only — no dose, route, or frequency is recommended here.
Free guides for both compounds
Each compound has a free educational guide covering mechanism, reported dosage ranges, reconstitution math, half-life, side effects and the combinations it appears in.
FAQ
What dosage of CJC-1295 and ipamorelin is commonly reported?
Neither compound has an approved human dose, so every figure in circulation is a community-reported example rather than a clinical recommendation. What is commonly described is roughly 100 mcg of CJC-1295 no-DAC paired with 100 mcg of ipamorelin per administration — the 100 mcg figure is a community 'saturation dose' heuristic, not a trial-proven threshold. Ipamorelin on its own is commonly reported in the 100–300 mcg range, and the DAC form of CJC-1295 in the region of 1000–2000 mcg per week because it lasts days rather than minutes. These are recorded as examples of what is reported, not as guidance for anyone to follow.
What is the difference between CJC-1295 with DAC and without DAC?
It is the single most consequential distinction in this stack and the one most write-ups skip. DAC stands for Drug Affinity Complex — a linker that covalently binds circulating albumin, so the peptide rides along with a long-lived blood protein. That extends its reported half-life from about 30 minutes without DAC to roughly 5.8–8.1 days with it. The practical consequence is frequency: the no-DAC form produces a short pulse and is reported as a daily or several-times-daily compound, while DAC produces a sustained elevation and is reported weekly. A protocol written for one form is simply wrong for the other.
Is CJC-1295 the same as Mod GRF 1-29?
CJC-1295 without DAC and Mod GRF 1-29 are the same molecule — a modified GHRH(1-29) analog. The two names are used interchangeably in the research market, which is a common source of confusion when comparing vendor listings or protocols. If a listing says 'CJC-1295' without specifying DAC, it is most often the no-DAC form, but the vial's own documentation is the authority.
Why are CJC-1295 and ipamorelin combined?
They act on two different receptors on the same pituitary cells. CJC-1295 is a GHRH analog binding the GHRH receptor; ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist. Because the receptors are distinct, the pairing is not redundant — unlike combining CJC-1295 with sermorelin or tesamorelin, which are all GHRH analogs competing for the same receptor. That is a mechanistic rationale, not an outcome claim: no controlled trial has studied the two administered together.
How do you reconstitute a CJC-1295 / ipamorelin blend vial?
The mechanical method is the same as any lyophilized peptide — add bacteriostatic water slowly down the vial wall and swirl gently, never shake. The arithmetic is what differs: a blend vial labelled '10 mg' usually holds 5 mg of each peptide, so the label figure is the combined mass and no single component's concentration can be derived from it. With a 5 mg + 5 mg vial, adding 2 mL gives 2.5 mg/mL of each, and a 100 mcg draw is 4 units on a U-100 syringe. Adding more water does not change how much peptide you have — it makes each small draw larger and therefore easier to measure accurately.
Does a blend vial let you adjust one peptide independently?
No, and this is the defining property of any pre-mixed vial. Once both peptides share a solution, one draw delivers a fixed ratio of both. With the usual 1:1 (5 mg + 5 mg) split that ratio happens to match the commonly reported 100 mcg + 100 mcg pairing, which is precisely why 1:1 blends are the ones sold. If you want the two varied independently, that requires two separate vials and two separate calculations.
Are CJC-1295 and ipamorelin FDA approved?
Neither is approved for any indication in any country. CJC-1295's clinical record is essentially a single Phase 1 pharmacokinetic trial of the DAC form in healthy subjects; ipamorelin was developed as NNC 26-0161, later studied for post-operative ileus, and that trial did not meet its primary endpoint. Both are prohibited by WADA in competitive sport. Material sold under either name is supplied for research use only.
What side effects are reported?
Commonly reported effects across the GH-axis class include injection-site reactions, transient flushing or head-rush, water retention, joint aches, tingling in the hands, and reduced insulin sensitivity with sustained use. Ipamorelin is frequently described as the better-tolerated half because, unlike older GHRPs such as GHRP-6, it is reported to raise cortisol and prolactin minimally and to stimulate appetite far less. Human safety data for both is thin and does not extend far beyond a few months, and no safety data exists for the combination specifically.
How long is a reconstituted blend good for?
Once reconstituted, GH-axis peptides are generally kept refrigerated at about 2–8 °C, protected from light, not frozen, and not shaken. Bacteriostatic water's 0.9% benzyl alcohol preservative is what allows a vial to be entered repeatedly rather than once — that is the functional reason it is used instead of plain sterile water. Follow the labeling that came with your material; nothing here is a storage instruction for a specific product.
Does Medibact sell CJC-1295 or ipamorelin?
No. Medibact does not sell peptides. It supplies USP-grade bacteriostatic water for injection made in an FDA-registered U.S. facility, publishes free educational guides for both compounds, and provides free reconstitution and blend calculators. All of it is research-use educational reference only.
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.